CAMP · Camp4 Therapeutics Corp
$3.19
+0.18 (+5.98%)
At close · Jul 24
Market Cap
$164.09M
Shares
51.93M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.01
Open$3.08
Day$2.94–3.22
52W$1.32–7.75
Avg vol 30d302K
Short int1.4M · 2.8% float · 9.1d
Short vol47%
Last earningsNov 21, 2024
DataOct 2024–Jul 2026
Filing10-Q · May 7
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 7, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.6 · elevated
Equity put/call 0.79
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−28%
below
RSI (14)
27
oversold
MACD trend
Negative
52-week position
26%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−25%
trailing
6-month return
−22%
trailing
YTD return
−51%
this year
Relative strength
−29%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
5 of 47 funds reported for Jun 30 · net +27.1K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.78% of float · ▲ +10.0% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
47 holders — near 1-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
+437%
Y/Y
EPS growth
+76%
Y/Y
Free cash flow
$-29.8M
Balance sheet
$109.5M
net cash
Quant / Vol
risk profile
Volatility
122%
annualized · 1-yr
Max drawdown
−58%
past year
ATR
13.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−28%
Bearish
RSI (14)
27
Neutral
MACD trend
Negative
Bearish
52-week position
26%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
5 of 47 funds reported for Jun 30 · net +27.1K sh shares · +3 new
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
2.78% of float · ▲ +10.0% MoM · 9.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
47 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $1
Now $3 · 26%
52-wk high $8
vs 200-day avg -32%
vs 50-day avg -28%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CAMP
this stock
Camp4 Therapeutics Corp
|
$164.09M | -50.9% | +436.5% | — | 2.8% |
|
ONC
BeOne Medicines Ltd.
|
$471.01B | +7.6% | +22179.2% | 958.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.16B | +4.4% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$68.78B | -15.4% | +20.8% | 16.0 | 3.3% |
|
ARGX
Argenx SE
|
$57.44B | +9.9% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CAMP | -22.8% | -25.3% | -22.2% | -31.1% | -50.9% |
| SPY | -1.7% | +0.7% | +6.4% | -1.2% | +8.3% |
| vs SPY | -21.2% | -26.0% | -28.6% | -30.0% | -59.2% |